Bhavana Pothuri, MD, MS is a Professor in the Departments of Ob/Gyn and Medicine, at the NYU Grossman School of Medicine, Perlmutter Cancer Center. She conducts and leads research on novel therapeutics to improve treatments for women with cancer. She serves in a leadership role as an Associate Clinical Trials Advisor for Ovarian and Endometrial Cancers in GOG Partners and she is an elected member of the Board of Directors for the Society of Gynecologic Oncology. She is the Director of Clinical Trials, Gynecologic Oncology, and the NRG Site PI for NYU Langone Health, Perlmutter Cancer Center. She has contributed to groundbreaking research in use of the PARP inhibitor, Niraparib as frontline maintenance treatment for ovarian cancer, as well as dostarlimab, PD-1 inhibitor which has been recently approved by the FDA for endometrial cancer. She has been invited to speak nationally and internationally for her contributions to research on PARPi in ovary cancer and check point inhibitors in endometrial cancer. Dr. Pothuri is committed to mentoring the next generation of physician scholars so they can continue the important work of improving care for gynecologic cancer patients.